Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis.
This study retrospectively investigated the efficacy and adverse events of applying a lower dose (0.5 g/m(2)) of monthly intravenous (IV) cyclophosphamide (CYC) for lupus nephritis in Korean patients. Adverse events occurred in 64 patients (61.5%) of 104 lupus nephritis patients who were treated with IV CYC, with the most common being those related to the gastrointestinal system, followed by infection, symptoms related to the hematopoietic system, skin and its appendages, reproductive system, and urinary system. Lower-dose IV CYC therapy resulted in renal remission or response in 76 patients (73.1%), which was as effective as the reported outcomes of higher-dose (0.75-1.0 g/m(2)) IV CYC regimens. Adverse events were more likely (with borderline statistical significance, p = 0.055) in those who achieved renal remission or response than in nonresponders.
Seong
Sang-Seokg
SS
Department of Internal Medicine, Konyang University Hospital, Daejeon 302-718, Republic of Korea.
Choi
Chan-Bum
CB
Yun
Hye-Ryeon
HR
Kim
Yoon-Jeong
YJ
Sung
Yoon-Kyoung
YK
Bae
Sang-Cheol
SC
D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D007723:Korea; D008181:Lupus Nephritis / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide